Another controversial prognostic factor is the translocation partner of MYC. Johnson et al reported that cases of MYC/BCL2 DHL in which MYC is partnered with a non IG locus had a better prognosis.[11] Two recent studies have shown that the adverse prognostic impact of MYC rearrangement correlates with MYC-IG translocation in de novo DLBCL patients treated with immunochemotherapy [29, 30]. Here, BCL2 is linked to diffuse large B-cell lymphoma.